Entities / Company
GSK.
British multinational pharmaceutical and biotechnology company
- Reports this week
- 11
- Active events
- 8
- Connections
- 575
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Clement Fourny joins Biodextris as CEO, a company that originated as a GSK development center.Some support1 report
-
GSK acquired Sierra Oncology.Some support2 reports
-
GSK and Ionis Pharmaceuticals co-developed the bepirovirsen drug for hepatitis B.Well supported12 reports
-
GSK built a joint venture with Pfizer and subsequently distributed a stake in that venture to shareholders.Some support1 report
-
GSK and Novartis are identified as major pharmaceutical companies.Some support1 report
-
GSK has licensed operational rights from HUTCHMED, a company based in China.Some support2 reports
-
Atiku Abubakar is named Tinubu's major opposition for 2027, while GSK is among foreign companies leaving Nigeria during Tinubu's annual leave.Some support1 report
-
GSK, Incyte, Vertex, and Janssen announced new collaboration agreements with Halozyme on September 21, 2026.Some support1 report
Earlier this month
-
GSK plans to close its vaccine facility in Dresden and consolidate production in Canada amid declining vaccine sales.Some support2 reports
-
Zhenhao Zhou, who leads Chimagen, has entered into a partnership with GSK.Some support1 report
-
GSK received rating updates, including an upgrade to buy, from banks like Berenberg, HSBC, and RBC.Some support2 reports
-
GSK announced positive results for lung cancer drugs. Separately, Andy Burnham is meeting executives to discuss growth plans, while oil prices rose due to strikes on Saudi infrastructure.Some support1 report
-
GSK and a Chinese pharmaceutical company saw stock climbs following the unveiling of drug trial results.Some support1 report
-
Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.Some support2 reports4 developments inside
-
GSK is submitting data to the FDA regarding potential expansion of its drug indications.Some support2 reports
-
Lung Foundation Australia discussed challenges related to COPD.Some support1 report
-
GSK is undergoing major operational shifts regarding its sites, including upgrading the Ware facility, opening a new flagship site in Cambridge, and shutting down its main R&D hub in Stevenage.Well supported13 reports2 developments inside
-
GSK is moving U.K.-based R&D operations to Cambridge near Addenbrooke's Hospital.Some support1 report
-
GSK and PainReform Ltd. are identified as competing healthcare companies for investment.Some support1 report
-
GSK and Evolus are identified as competing healthcare companies in the market.Some support2 reports
-
GSK is advancing its experimental influenza vaccine into late-stage development following a portfolio review.Some support1 report
-
GSK is launching a vaccine in Europe and has appointed Sanjay Gurunathan as Head of Vaccines.Some support1 report
-
Deutsche Bank provided a rating for GSK stock, while Investec adjusted and Deutsche Bank downgraded Burberry stock ratings.Some support1 report
-
AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.Some support1 report2 developments inside
-
AstraZeneca and GSK, along with Aurora Cannabis Inc., are involved in hiring Faris El Refaie for global commercial leadership, gaining experience in the pharmaceutical sector.Some support3 reports
-
Moderna's higher pricing is contrasted with GSK's and Pfizer's pricing in the context of a joint procurement agreement, which was deemed vital by Hadja Lahbib.Some support1 report
-
GSK and Amgen are major biopharma players.Some support1 report
-
Pharmaceutical companies, including AbbVie and GSK, funded studies comparing drug spending, with Michael Johnson discussing Australia vs. New Zealand spending.Some support1 report
-
Moncef Slaoui, a three-decade veteran, was associated with GSK.Some support2 reports
-
GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.Speculative1 report1 development inside
-
GSK and Gilead Sciences received multiple approvals for pipeline products and benchmarked performance against competitors.Some support1 report
-
Bio Farma, GSK, and the Gates Foundation are collaborating on developing an M72 vaccine candidate in Indonesia.Some support1 report
One to three months ago
-
FDA granted designation for a drug under Gibbs' leadership, involving GSK and Gilead Sciences.Some support1 report
-
The House Judiciary Committee investigated Pfizer's vaccine timing, with Jim Jordan citing claims about delayed disclosure, while a Pfizer executive moved to GSK.Speculative1 report1 development inside
-
GSK appointed Tina Graves as General Manager for Canadian operations. Graves has experience at both Pfizer and GSK.Some support1 report
-
GSK and ABB identified a shared need for advanced compliance and risk management solutions.Some support2 reports
-
GSK has successfully gained market approval in Japan for its product Hibsago, following efforts to secure market access in the country.Some support2 reports
-
GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.Some support1 report1 development inside
-
GSK is seeking priority review for its Jemperli application, and the FDA set the PDUFA action date.Some support2 reports
-
Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.Some support1 report2 developments inside
-
Collaboration revenue realization from Pfizer and GSK backing royalty financing for Spero Therapeutics.Some support1 report
-
A report detailing the stock performance of several UK companies, including Fresnillo, WPP, Anglo American, and GSK, on August 1, 2026.Some support1 report
-
An MoU has been made to enhance comprehensive healthcare in Việt Nam, involving Thong Nhat Hospital and GSK.Some support1 report
-
GSK and AstraZeneca both aim to hit ambitious revenue targets.Some support1 report
-
GSK has launched a competing ROS1 therapy, while Nuvation Bio Inc. presented relevant data at a major medical conference.Some support1 report
-
Life sciences sector is experiencing a boom driven by manufacturing and healthcare, leading to a shift in focus from Greater Boston. GSK is expanding its presence with a major $800M project.Some support1 report1 development inside
-
GSK's pre-let activity is driving up demand for lab space in the life sciences sector, monitored by market analysts.Some support1 report
-
On July 29, 2026, various financial markets showed activity, including CaixaBank topping earnings estimates, EssilorLuxottica beating profit estimates, and FED policy impacting European bond yields.Some support2 reports
-
AstraZeneca cancelled its £450m expansion in Liverpool, while GSK announced a £400m investment in a new R&D center and relocated scientists from Stevenage.Some support1 report
-
GSK conducted pivotal Phase III trials in China and is seeking US FDA Breakthrough Therapy Designation.Some support1 report
-
GSK operates in South Korea regarding health policy, aligning with UN standards for aging society.Some support1 report
-
Companies like BAE Systems, GSK, AstraZeneca, and HSBC are benefiting from geopolitical tensions, market recoveries, and strong market conditions in Europe.Some support2 reports5 developments inside
-
HSBC analyst downgraded AstraZeneca's rating, noting that AstraZeneca trails GSK in stock performance.Some support1 report
-
FDA approved Jideytro for NSCLC treatment.Some support1 report
-
GSK and large pharmaceutical companies are facing revenue exposure and market pressures.Some support1 report
-
HSBC and RBC have issued rating commentary on GSK, which is headquartered in London.Some support2 reports
-
The European Medicines Agency reviews submissions for pharmaceutical products.Some support2 reports
-
GSK's failed trials opened a market niche for Trevi Therapeutics.Some support1 report1 development inside
-
HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.Some support1 report
-
Prasco managed coverage and pricing discussions with GSK in January 2026.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around GSK this week
News at the entities that move GSK most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves GSK
-
European Medicines Agency StructuralBoth the FDA and the European Medicines Agency are evaluating NervGen's lead therapeutic candidate.Moves GSK
-
AstraZeneca OperationalAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves GSK
-
Donald Trump OperationalThe Trump administration utilized the Department of Health & Human Services for an AI tool.Moves GSK
-
Merck OperationalEli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Moves GSK
-
Prologis StructuralMarketBeat featured Teledyne e2v and Prologis as a top growth stock pick providing enabling technologies in the US.Moves GSK
Connections
The 40 strongest of 575, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Haleon Structural
Haleon was established as a corporate spin-off from GSK, which previously held a controlling stake in the entity.
-
FDA Structural
GSK's ability to market its pharmaceutical products is formally dependent on regulatory approval and review by the FDA.
-
Sanjay Gurunathan Structural
Sanjay Gurunathan holds the functional role of Head of Vaccines within GSK.
-
Tony Wood Structural
Tony Wood holds the formal position of Chief Scientific Officer at GSK.
-
Emma Walmsley Structural
Emma Walmsley holds the formal and executive role of CEO for GSK.
-
Julie Brown Structural
Julie Brown holds the executive role of Chief Financial Officer at GSK.
-
Patrick Vallance Structural
Patrick Vallance held the position of head of research at GSK.
-
Spero Therapeutics (United States) Structural
GSK acts as the development partner and rights holder for Spero Therapeutics, providing milestone payments and receiving collaboration revenue.
Show all 40 connections
-
AstraZeneca Operational
GSK and AstraZeneca are direct competitors in the pharmaceutical market, facing rivalry in oncology and respiratory sectors.
-
CureVac Operational
CureVac and GSK have established an operational partnership involving the sale of vaccine rights and shared involvement in legal disputes.
-
Cambridge Structural
GSK is establishing its global R&D headquarters and flagship operational base within the Cambridge area.
-
Stevenage Operational
GSK is closing its main R&D hub, which was a major operational presence in Stevenage.
-
Stevenage Transactional
GSK is ceasing operations at its R&D hub located in Stevenage.
-
Ionis Pharmaceuticals Operational
GSK and Ionis Pharmaceuticals are actively co-developing the experimental drug bepirovirsen for the treatment of Hepatitis B.
-
Alector (United States) Operational
GSK and Alector maintain a strategic partnership to co-develop neurodegenerative disease treatments, including AL101.
-
Cambridge Biomedical Campus Structural
GSK is establishing a major, long-term R&D center and integrating its operations into the specialized Cambridge Biomedical Campus ecosystem.
-
Scynexis Operational
GSK and Scynexis maintain an active, complex relationship involving drug licensing, milestone payments, and ongoing disputes.
-
Tina Graves Structural
Tina Graves is employed by GSK as General Manager for Canadian operations, following previous global leadership roles at the company.
-
Merck Operational
GSK and Merck are direct competitors in the market due to their production and sale of combination MMR shots.
-
Andy Burnham Transactional
Andy Burnham publicly welcomed GSK's £400 million investment in a new facility, acknowledging the corporate action within the political context.
-
Prologis Structural
Prologis is currently developing a new R&D centre dedicated to supporting GSK's operational needs.
-
Addenbrooke's Hospital Structural
GSK operates clinical and R&D units utilizing the facilities of Addenbrooke's Hospital.
-
Royalty Pharma Structural
Royalty Pharma holds royalties on GSK's Trelegy, establishing a persistent financial dependency.
-
Moderna Operational
Moderna and GSK are direct competitors in the pharmaceutical market, specifically in vaccine development and marketing.
-
Dresden Structural
GSK is closing its vaccine facility located in Dresden.
-
Andrew Witty Structural
Andrew Witty previously served as the leader of GSK from 2008 to 2017.
-
Pfizer Operational
Pfizer and GSK are actively coupled through market competition and a formal joint venture in the pharmaceutical sector.
-
Moncef Slaoui Structural
Moncef Slaoui held a long-term employment position at GSK.
-
European Medicines Agency Structural
The European Medicines Agency evaluates GSK's product submissions as part of the market authorization process in the EU.
-
Donald Trump Operational
Trump's political policies and regulatory actions directly influence GSK's market, operational environment, and policy landscape.
-
China Operational
GSK actively utilizes China for pivotal clinical trials and sources licensed pharmaceutical products from companies based there.
-
Ware Structural
GSK is utilizing the Ware site for R&D facility upgrades and staff relocation.
-
Royal Bank of Canada Operational
RBC provides financial rating commentary and market coverage on GSK shares.
-
Deutsche Bank Transactional
Deutsche Bank issued a stock rating for GSK, representing a specific informational exchange.
-
Theravance Biopharma (United States) Transactional
Theravance sold royalty interests in Trelegy Ellipta to GSK across multiple transactions.
-
AstraZeneca Operational
GSK and AstraZeneca have formed a partnership to gain access to the mainland China market.
-
Novartis Structural
GSK and Novartis are structurally linked via tiered royalty payments while also actively competing in the pharmaceutical market.
-
IRC Operational
IRC is functionally involved in assessing efficacy endpoints for a clinical trial conducted by GSK.
-
Zhenhao Zhou Operational
Zhenhao Zhou leads Chimagen, which is currently engaged in a partnership with GSK.
-
Seng Gee Lim Structural
GSK provides financial backing for international studies led by Seng Gee Lim.
History
Events by the month they beganSeptember 2026
28 events- Clement Fourny joins Biodextris as CEO, a company that originated as a GSK development center.
- GSK acquired Sierra Oncology.
- GSK built a joint venture with Pfizer and subsequently distributed a stake in that venture to shareholders.
- GSK and Novartis are identified as major pharmaceutical companies.
- GSK has licensed operational rights from HUTCHMED, a company based in China.
- Atiku Abubakar is named Tinubu's major opposition for 2027, while GSK is among foreign companies leaving Nigeria during Tinubu's annual leave.
- GSK, Incyte, Vertex, and Janssen announced new collaboration agreements with Halozyme on September 21, 2026.
- GSK plans to close its vaccine facility in Dresden and consolidate production in Canada amid declining vaccine sales.
- Zhenhao Zhou, who leads Chimagen, has entered into a partnership with GSK.
- GSK received rating updates, including an upgrade to buy, from banks like Berenberg, HSBC, and RBC.
- GSK announced positive results for lung cancer drugs. Separately, Andy Burnham is meeting executives to discuss growth plans, while oil prices rose due to strikes on Saudi infrastructure.
- GSK and a Chinese pharmaceutical company saw stock climbs following the unveiling of drug trial results.
- GSK is submitting data to the FDA regarding potential expansion of its drug indications.
- Lung Foundation Australia discussed challenges related to COPD.
- GSK is moving U.K.-based R&D operations to Cambridge near Addenbrooke's Hospital.
- GSK and PainReform Ltd. are identified as competing healthcare companies for investment.
- GSK and Evolus are identified as competing healthcare companies in the market.
- GSK is advancing its experimental influenza vaccine into late-stage development following a portfolio review.
- GSK is launching a vaccine in Europe and has appointed Sanjay Gurunathan as Head of Vaccines.
- Deutsche Bank provided a rating for GSK stock, while Investec adjusted and Deutsche Bank downgraded Burberry stock ratings.
- AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
- AstraZeneca and GSK, along with Aurora Cannabis Inc., are involved in hiring Faris El Refaie for global commercial leadership, gaining experience in the pharmaceutical sector.
- Moderna's higher pricing is contrasted with GSK's and Pfizer's pricing in the context of a joint procurement agreement, which was deemed vital by Hadja Lahbib.
- GSK and Amgen are major biopharma players.
- Pharmaceutical companies, including AbbVie and GSK, funded studies comparing drug spending, with Michael Johnson discussing Australia vs. New Zealand spending.
- Moncef Slaoui, a three-decade veteran, was associated with GSK.
- GSK and Gilead Sciences received multiple approvals for pipeline products and benchmarked performance against competitors.
- Bio Farma, GSK, and the Gates Foundation are collaborating on developing an M72 vaccine candidate in Indonesia.
August 2026
12 events- FDA granted designation for a drug under Gibbs' leadership, involving GSK and Gilead Sciences.
- GSK appointed Tina Graves as General Manager for Canadian operations. Graves has experience at both Pfizer and GSK.
- GSK and ABB identified a shared need for advanced compliance and risk management solutions.
- GSK has successfully gained market approval in Japan for its product Hibsago, following efforts to secure market access in the country.
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
- GSK is seeking priority review for its Jemperli application, and the FDA set the PDUFA action date.
- Collaboration revenue realization from Pfizer and GSK backing royalty financing for Spero Therapeutics.
- A report detailing the stock performance of several UK companies, including Fresnillo, WPP, Anglo American, and GSK, on August 1, 2026.
- An MoU has been made to enhance comprehensive healthcare in Việt Nam, involving Thong Nhat Hospital and GSK.
- GSK and AstraZeneca both aim to hit ambitious revenue targets.
- GSK has launched a competing ROS1 therapy, while Nuvation Bio Inc. presented relevant data at a major medical conference.
- GSK's pre-let activity is driving up demand for lab space in the life sciences sector, monitored by market analysts.
July 2026
14 events- GSK is undergoing major operational shifts regarding its sites, including upgrading the Ware facility, opening a new flagship site in Cambridge, and shutting down its main R&D hub in Stevenage.
- Life sciences sector is experiencing a boom driven by manufacturing and healthcare, leading to a shift in focus from Greater Boston. GSK is expanding its presence with a major $800M project.
- On July 29, 2026, various financial markets showed activity, including CaixaBank topping earnings estimates, EssilorLuxottica beating profit estimates, and FED policy impacting European bond yields.
- AstraZeneca cancelled its £450m expansion in Liverpool, while GSK announced a £400m investment in a new R&D center and relocated scientists from Stevenage.
- GSK conducted pivotal Phase III trials in China and is seeking US FDA Breakthrough Therapy Designation.
- GSK operates in South Korea regarding health policy, aligning with UN standards for aging society.
- HSBC analyst downgraded AstraZeneca's rating, noting that AstraZeneca trails GSK in stock performance.
- FDA approved Jideytro for NSCLC treatment.
- GSK and large pharmaceutical companies are facing revenue exposure and market pressures.
- HSBC and RBC have issued rating commentary on GSK, which is headquartered in London.
- The European Medicines Agency reviews submissions for pharmaceutical products.
- GSK's failed trials opened a market niche for Trevi Therapeutics.
- HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.
- Prasco managed coverage and pricing discussions with GSK in January 2026.
Show 1 earlier month
June 2026
6 events- GSK and Ionis Pharmaceuticals co-developed the bepirovirsen drug for hepatitis B.
- Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
- The House Judiciary Committee investigated Pfizer's vaccine timing, with Jim Jordan citing claims about delayed disclosure, while a Pfizer executive moved to GSK.
- Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.
- Companies like BAE Systems, GSK, AstraZeneca, and HSBC are benefiting from geopolitical tensions, market recoveries, and strong market conditions in Europe.